By RANDOLPH E. SCHMID
The Associated PressMonday, November 6, 2006; 6:19 PM
WASHINGTON --
"The first test of a potential new gene therapy for HIV _ the virus that causes AIDS _ was encouraging enough for researchers to launch a more extensive trial.
"The goal of this phase I trial was safety and feasibility, and the results established that," said lead researcher Dr. Carl June. "But the results also hint at something much more."
In addition to showing that the treatment was possible and didn't endanger the patients, the amount of virus in the subjects remained steady or decreased during the study, which involved just five people with chronic HIV infection.
One patient had a sustained decrease in the amount of virus, and immune cells and strength of the immune system increased in four patients during the nine-month study..."
Article available on the Washington Post's website.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment